Hydrogen sulfide tags a ubiquitin ligase to clear the NLRP3 inflammasome in aging mouse hearts
In mice, hydrogen sulfide modifies the enzyme UBE3C so it destroys NLRP3, calming inflammation and senescence in heart cells. Mouse and cell work only.
Summary
As the heart ages, an inflammatory protein complex called the NLRP3 inflammasome becomes overactive and damages heart muscle cells. This study asked whether hydrogen sulfide (H2S), a gas the body makes naturally, can restrain it. Mice that could not make H2S had lower cardiac function and more markers of senescence and inflammation. In mice with D-galactose-induced aging, an H2S donor (NaHS) restored heart function and lowered oxidative stress, glycation products and senescence markers. Mechanistically, H2S attaches sulfur groups to an enzyme called UBE3C at two specific sites. That helps UBE3C bind NLRP3 and mark it for disposal through the cell's autophagy-lysosome pathway. This is mouse and cell research using a chemically induced aging model, so it is not evidence of benefit in people. The summary is based on the abstract only.
Detailed Summary
Why this matters: Heart function declines with age, and chronic low-grade inflammation is a driver. The NLRP3 inflammasome, a protein complex that triggers the inflammatory cytokines IL-1β and IL-18, is overactive in the aging heart and can injure cardiomyocytes. Finding ways to switch it off at the source is a major aim of cardiac aging research.
What was studied: Researchers tested whether hydrogen sulfide, a gasotransmitter produced in part by the enzyme cystathionine-γ-lyase (CSE), protects the aging heart. They used CSE-deficient mice, which have low H2S, and mice given D-galactose, a commonly used chemical model of accelerated aging. They treated the D-galactose mice and cardiomyocytes with the H2S donor NaHS.
Key results: CSE-deficient mice had lower H2S and worse cardiac function than wild-type controls. They also showed higher p53 and p21 (senescence regulators), more advanced glycation end-products, and higher IL-18 and IL-1β. In the D-galactose model, NaHS restored cardiac function and raised H2S, superoxide dismutase and catalase. It lowered malondialdehyde, reactive oxygen species, AGEs, p53, p21, senescence-associated β-galactosidase and NLRP3 activation. Mechanistically, UBE3C promoted NLRP3 degradation through K29-linked ubiquitination via the autophagic-lysosomal pathway. NaHS strengthened UBE3C-NLRP3 binding through S-sulfhydration at cysteines 158 and 395, and mutating those sites abolished the interaction.
Implications: The work outlines a specific pathway from H2S to UBE3C modification to NLRP3 clearance, linking sulfur signaling to inflammation and senescence in the heart. It supports H2S biology and UBE3C as targets worth studying in cardiac aging.
Caveats: These are mouse and cell findings in a chemically induced aging model, not naturally aged animals, and no lifespan data are reported. Nothing here shows benefit or safety in people, and this summary draws on the abstract only.
Key Findings
- CSE-deficient mice had low H2S, reduced cardiac function, and higher p53, p21, AGEs, IL-1β and IL-18 than wild-type mice.
- NaHS, an H2S donor, restored cardiac function in aged mice and lowered ROS, AGEs and senescence markers in the D-galactose model.
- Mechanism: UBE3C drives NLRP3 degradation through K29-linked ubiquitination via the autophagic-lysosomal pathway.
- H2S S-sulfhydrates UBE3C at Cys158 and Cys395, boosting NLRP3 binding; mutating these sites abolished the interaction.
- The abstract reports no lifespan data and no human data; evidence is preclinical mechanism and function.
Methodology
Preclinical study using CSE-knockout mice versus wild-type, a D-galactose-induced cardiac aging model in mice and cardiomyocytes, and treatment with the H2S donor NaHS. Mechanistic work included ubiquitination assays, binding studies and cysteine-site mutations. Sample sizes and statistics are not given in the abstract.
Study Limitations
The summary is based on the abstract only, so sample sizes, dosing, statistics and effect magnitudes could not be assessed. D-galactose models accelerated aging chemically and may not reflect natural aging, and no lifespan or human data are reported. NaHS is a fast-releasing donor, and whether its effects translate to safe, sustained dosing is unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
